Related Experiment Video
Updated: Apr 29, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
HER2-targeted therapy for early-stage breast cancer: a comprehensive review
Abstract:
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer, and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for millions of women with early-stage and advanced HER2-positive breast cancer. This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adjuvant and neoadjuvant settings--settings in which tremendous progress has been made. Novel approaches, including the use of combinations of HER2-targeted therapies, are examined. Future challenges include refining such treatments, reducing toxicity in those who have low-risk disease, and simultaneously developing innovative therapies for patients who remain at high risk for relapse with existing treatment options.
Insights
HER2-targeted therapies have transformed breast cancer treatment, significantly improving outcomes for patients with HER2-positive disease. Ongoing research focuses on refining these treatments and developing new options for high-risk patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The identification of human epidermal growth factor receptor 2 (HER2) has revolutionized breast cancer treatment.
- HER2-targeted therapies have led to substantial improvements in clinical outcomes for patients with HER2-positive breast cancer.
Purpose of the Study:
- To review the current treatment landscape for primary, nonmetastatic HER2-positive breast cancer in adjuvant and neoadjuvant settings.
- To examine novel therapeutic strategies, including combination HER2-targeted therapies.
- To identify future challenges and directions in managing HER2-positive breast cancer.
Main Methods:
- Literature review of studies on HER2-positive breast cancer treatment.
- Analysis of clinical outcomes associated with HER2-targeted therapies.
- Discussion of emerging treatment paradigms and future research needs.
Main Results:
- HER2-targeted therapies have markedly improved outcomes in early-stage and advanced HER2-positive breast cancer.
- Significant progress has been achieved in both adjuvant and neoadjuvant treatment settings.
- Combination therapies represent a promising novel approach.
Conclusions:
- HER2-targeted therapies are a cornerstone in managing HER2-positive breast cancer.
- Future efforts should focus on optimizing treatment efficacy, minimizing toxicity in low-risk patients, and developing innovative therapies for high-risk individuals.
- Continued research is crucial for addressing unmet needs in HER2-positive breast cancer management.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...